TEZRULY
openFDA label record#
This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.
Verified complete openFDA source JSON
- Brand name
- TEZRULY
- Generic name
- TERAZOSIN
- Manufacturer
- ANI Pharmaceuticals, Inc.
- Product type
- HUMAN PRESCRIPTION DRUG
- SPL set ID
- 69582e0c-6569-490c-8c14-999f3750336f
- SPL ID
- 0d2b0b80-5201-473a-9b43-f5c2127f6f7c
- Version
- 3
- Effective date
- 2025-04-18
- Source export date
- 2026-11-13
- Source partition
- 9
- Source file
- https://download.open.fda.gov/drug/label/drug-label-0009-of-0014.json.zip
- Source object key
- raw/openfda/drug-label/2026-11-13/48e89e7994339d0e23bed7c09f727a47746d1fbd440ad66960650182851cb8a9/drug-label-0009-of-0014.json.zip
- Source manifest SHA-256
- 8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
- Import run
- 20261116T150851Z
- Imported at
- 2026-11-16 16:57:58
| Harmonized routes |
|---|
| ORAL |
Harmonized identifier links#
Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.
| Type | Scope | Identifier | Source field |
|---|---|---|---|
| application applno | NDA | 218139 | derived:openfda.application_number |
| application number | NDA218139 | openfda.application_number | |
| brand name | TEZRULY | openfda.brand_name | |
| generic name | TERAZOSIN | openfda.generic_name | |
| manufacturer name | ANI Pharmaceuticals, Inc. | openfda.manufacturer_name | |
| ndc | package | 70954-592-10 | openfda.package_ndc |
| ndc | product | 70954-592 | openfda.product_ndc |
| ndc11 | package | 70954059210 | derived:openfda.package_ndc |
| rxcui | 2689139 | openfda.rxcui | |
| rxcui | 2689133 | openfda.rxcui | |
| spl id | 0d2b0b80-5201-473a-9b43-f5c2127f6f7c | id | |
| spl set id | 69582e0c-6569-490c-8c14-999f3750336f | set_id | |
| unii | D32S14F082 | openfda.unii |
Warnings cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
5 WARNINGS AND PRECAUTIONS Syncope and “First-dose” Effect: Advise patients about the possibility of symptoms related to postural hypotension and to avoid situations where injury could result should syncope occur, especially when starting TEZRULY. (5.1) Orthostatic Hypotension: Dizziness, lightheadedness, and palpitations can occur with use of TEZRULY. Advise patients to take their first dose of TEZRULY at bedtime and to avoid driving or hazardous tasks for 12 hours after the first dose, after a dosage increase, and after interruption of therapy when treatment is resumed. (5.2) Risk of Hypotension with Concomitant Use of Other Antihypertensive Agents and Phospodiesterase Type 5 Inhibitors (PDE5-I): Concomitant administration of TEZRULY with antihypertensives or phosphodiesterase-5 (PDE-5) inhibitors can result in additive blood pressure lowering effects and symptomatic hypotension (5.3). Priapism: Advise patients about the possibility and seriousness of priapism. (5.4) Intraoperative Floppy Iris Syndrome: Advise patients considering cataract surgery to tell their ophthalmologist that they have taken terazosin as Intraoperative Floppy Iris Syndrome as been observed during cataract surgery in some patients. (5.5) Prostatic Cancer: Screen for the presence of prostatic cancer prior to treatment for BPH and at regular intervals afterwards. (5.6) 5.1 Syncope and ‘‘First-dose’’ Effect TEZRULY, like other alpha-1-adrenoceptors antagonists, can cause marked lowering of blood pressure, especially postural hypotension, and syncope in association with the first dose or first few days of therapy [see Warnings and Precautions (5.2)] . A similar effect can be anticipated if therapy is interrupted for several days and then restarted. Syncope has also been reported with other alpha-1-adrenoceptors antagonists in association with rapid dosage increases or the introduction of another antihypertensive drug. Syncope is believed to be due to an excessive postural hypotensive effect, although occasionally the syncopal episode has been preceded by a bout of severe supraventricular tachycardia with heart rates of 120-160 beats per minute. Additionally, the possibility of the contribution of hemodilution to the symptoms of postural hypotension should be considered. To decrease the likelihood of syncope or excessive hypotension, initiate treatment with a 1 mg dose of terazosin, given at bedtime. Higher doses (e.g., 2 to 10 mg) are not indicated as initial therapy. Then slowly increase the dose [see Dosage and Administration (2.1 and 2.2)] , and add additional antihypertensive agents with caution. Advise patients to avoid situations, such as driving or hazardous tasks, where injury could result should syncope occur during initiation of therapy. In early investigational studies, where increasing single doses up to 7.5 mg were given at 3-day intervals, tolerance to the first dose phenomenon did not necessarily develop and the ‘‘first-dose” effect could be observed at all doses. Syncopal episodes occurred in 3 of the 14 subjects given terazosin at doses of 2.5, 5 and 7.5 mg, which are higher than the recommended initial dose; in addition, severe orthostatic hypotension (blood pressure falling to 50/0 mmHg) was seen in two others and dizziness, tachycardia, and lightheadedness occurred in most subjects. These adverse effects all occurred within 90 minutes of dosing. In three placebo-controlled BPH studies 1, 2, and 3 [see Clinical Pharmacology (1 2 )] , the incidence of postural hypotension in the terazosin treated patients was 5.1%, 5.2%, and 3.7% respectively. In multiple dose clinical trials involving nearly 2000 hypertensive patients treated with terazosin, syncope was reported in about 1% of patients. Syncope was not necessarily associated only with the first dose. If syncope occurs, place the patient in a recumbent position and treat supportively as necessary. There is evidence that the orthostatic effect of terazosin is greater, even in chronic use, shortly after dosing. The risk of the events is greatest during the initial seven days of treatment but continues at all time intervals. 5.2 Orthostatic Hypotension While syncope is the most severe orthostatic effect of terazosin, other symptoms of lowered blood pressure [see Warnings and Precautions (5.1)] , such as dizziness, lightheadedness and palpitations were more common and occurred in some 28% of patients in clinical trials of hypertension. In BPH clinical trials, 21% of the patients experienced one or more of the following: dizziness, hypotension, postural hypotension, syncope, and vertigo. Patients with occupations in which such events represent potential problems should be treated with particular caution. Advise patients to take their first dose of TEZRULY at bedtime and to avoid driving or hazardous tasks for 12 hours after the first dose, after a dosage increase, and after interruption of therapy when treatment is resumed. 5.3 Risk of Hypotension with Concomitant Use of Other Antihypertensive Agents and Phosphodiesterase Type 5 Inhibitors (PDE5-I) Concomitant use of TEZRULY with other anti-hypertensive agents, especially the calcium channel blocker verapamil, can increase the risk of hypotension. To reduce the risk of hypotension, dosage reduction and re-titration of either agent may be necessary [see Warnings and Precautions (5.1 and 5.2)] . Hypotension has been reported when terazosin has been used with phosphodiesterase-5 (PDE-5) inhibitors. Therefore, PDE-5 inhibitor therapy should be initiated at the lowest dose in patients taking TEZRULY. 5.4 Priapism Rarely (probably less than once in every several thousand patients) terazosin and other alpha-1-selective adrenoceptor antagonist have been associated with priapism (painful penile erection, sustained for hours and unrelieved by sexual intercourse or masturbation). Because this condition can lead to permanent impotence if not promptly treated, advise patients about the seriousness of the condition and the need to seek immediate medical attention at an emergency room. 5.5 Prostatic Cancer Carcinoma of the prostate and BPH present with many of the same symptoms and frequently co-exist. Therefore, examine patients thought to have BPH prior to starting TEZRULY therapy to rule out the presence of carcinoma of the prostate. 5.6 Intraoperative Floppy Iris Syndrome Intraoperative floppy iris syndrome (IFIS) has been observed during cataract surgery in some patients on/or previously treated with alpha-1-adrenoceptor antagonists. This variant of small pupil syndrome is characterized by the combination of a flaccid iris that billows in response to intraoperative irrigation currents, progressive intraoperative miosis despite preoperative dilation with standard mydriatic drugs, and potential prolapse of the iris toward the phacoemulsification incisions. The patient’s ophthalmologist should be prepared for possible implementation of intraoperative preventive measures and modifications to surgical techniques during phacoemulsification surgery to reduce overall complication rates. There does not appear to be a benefit of stopping alpha-1-adrenoceptor antagonists therapy prior to cataract surgery. 5.7 Laboratory Tests Small but statistically significant decreases in hematocrit, hemoglobin, white blood cells, total protein and albumin were observed in controlled clinical trials. These laboratory findings suggested the possibility of hemodilution. Treatment with terazosin for up to 24 months had no significant effect on prostate specific antigen (PSA) levels.
Adverse reactions cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
adverse reactions
6 ADVERSE REACTIONS The following clinically significant adverse reactions are described elsewhere in the labeling: Syncope and ‘‘First-dose’’ Effect [see Warnings and Precautions (5.1)] Orthostatic Hypotension [see Warnings and Precautions (5.2)] Priapism [see Warnings and Precautions (5.3)] Intraoperative Floppy Iris Syndrome [see Warnings and Precautions (5.5)] In treatment of BPH, the most common adverse reactions (≥1% of patients and at a higher incidence than placebo) were asthenia, flu syndrome, postural hypotension, nausea, somnolence, vertigo, dyspnea, nasal congestion/rhinitis, blurred vision/amblyopia and erectile dysfunction. (6.1) In treatment of hypertension, the most common adverse reactions where the incidence on terazosin was ≥ 5%, where the incidence on terazosin was at least 2% and greater than placebo or where the reaction was of particular interest were asthenia, back pain, pain in the extremities, headache, palpitations, postural hypotension, tachycardia, nausea, edema, peripheral edema, weight gain, depression, dizziness, libido, decreased, nervousness, paresthesia, somnolence, dyspnea, nasal congestion, sinusitis, blurred vision, and erectile dysfunction. (6.1) To report SUSPECTED ADVERSE REACTIONS, contact ANI Pharmaceuticals, Inc. at 1-855-204-1431 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical studies are conducted under widely varying conditions, adverse reactions rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice. Benign Prostatic Hyperplasia The incidence rates presented below are based on combined data from six placebo-controlled trials involving once-daily administration of terazosin at doses ranging from 1 to 20 mg. Table 1 summarizes those adverse events reported for patients in these trials when the incidence rate in the terazosin group was at least 1% and was greater than that for the placebo group, or where the reaction is of clinical interest. Asthenia, postural hypotension, dizziness, somnolence, nasal congestion/rhinitis, and impotence were the only events that were significantly (p ≤ 0.05) more common in patients receiving terazosin than in patients receiving placebo. The incidence of urinary tract infection was significantly lower in the patients receiving terazosin than in patients receiving placebo. An analysis of the incidence rate of hypotensive adverse reactions [see Warnings and Precautions (5.1, 5.2)] adjusted for the length of drug treatment has shown that the risk of the reactions is greatest during the initial seven days of treatment but continues at all time intervals. Table 1. Adverse Reactions Reported During Placebo-Controlled Studies of Terazosin in Patients with Benign Prostatic Hyperplasia Body System Terazosin (N=636) % Placebo (N=360) % BODY AS A WHOLE †Asthenia 7* 3 Flu Syndrome 2 2 Headache 5 6 CARDIOVASCULAR SYSTEM Hypotension 1 1 Palpitations 1 1 Postural Hypotension 4* 1 Syncope 1 0 DIGESTIVE SYSTEM Nausea 2 1 METABOLIC AND NUTRITIONAL DISORDERS Peripheral Edema 1 0 Weight Gain 1 0 NERVOUS SYSTEM Dizziness 9* 4 Somnolence 4 2 Vertigo 1 0 RESPIRATORY SYSTEM Dyspnea 2 1 Nasal Congestion/Rhinitis 2* 0 UROGENITAL SYSTEM Erectile Dysfunction 2* 1 Urinary Tract Infection 1 4* † Includes weakness, tiredness, lassitude and fatigue. * p ≤ 0.05, comparison between groups. Additional adverse reactions have been reported, but these are, in general, not distinguishable from symptoms that might have occurred in the absence of exposure to terazosin. The safety profile of patients treated in the long-term open-label study was similar to that observed in the controlled studies. Adverse reactions were usually transient and mild or moderate in intensity, but sometimes were serious enough to interrupt treatment. In the placebo-controlled clinical trials, the rates of premature termination due to adverse reactions were not statistically different between the placebo and terazosin groups. Adverse reactions that were bothersome, reported as the reason for discontinuation of therapy by at least 0.5% of the terazosin group and reported more often than in the placebo group are shown in Table 2. Table 2. Discontinuation Rates During Placebo-Controlled Studies of Terazosin in Patients with Benign Prostatic Hyperplasia Body System Terazosin (N=636) % Placebo (N=360) % BODY AS A WHOLE Fever 0.5% 0.0% Headache 1.1% 0.8% CARDIOVASCULAR SYSTEM Postural Hypotension 0.5% 0.0% Syncope 0.5% 0.0% DIGESTIVE SYSTEM Nausea 0.5% 0.3% NERVOUS SYSTEM Dizziness 2.0% 1.1% Vertigo 0.5% 0.0% RESPIRATORY SYSTEM Dyspnea 0.5% 0.3% SPECIAL SENSES Blurred Vision/Amblyopia 0.6% 0.0% UROGENITAL SYSTEM Urinary Tract Infection 0.6% 0.0% Hypertension The prevalence rates presented below are based on combined data from fourteen placebo-controlled studies involving once-daily administration of terazosin, as monotherapy or in combination with other antihypertensive agents, at doses ranging from 1 to 40 mg. Table 3 summarizes those adverse reactions reported for patients in these trials where the prevalence rate in the terazosin group was at least 5%, where the prevalence rate for the terazosin group was at least 2% and was greater than the prevalence rate for the placebo group, or where the reaction is of particular interest. Asthenia, blurred vision, dizziness, nasal congestion, nausea, peripheral edema, palpitations and somnolence were the only symptoms that were significantly (p < 0.05) more common in patients receiving terazosin than in patients receiving placebo. Similar adverse reaction rates were observed in placebo-controlled monotherapy trials. Table 3. Adverse Reactions Reported During Placebo-Controlled Studies of Terazosin in Patients with Hypertension Body System Terazosin (N=859) % Placebo (N=506) % BODY AS A WHOLE †Asthenia 11* 4 Back Pain 2 1 CARDIOVASCULAR SYSTEM Palpitations 4* 1 Postural Hypotension 1 0 Tachycardia 2 1 DIGESTIVE SYSTEM Nausea 4* 1 METABOLIC AND NUTRITIONAL DISORDERS Peripheral Edema 6* 2 Weight Gain 1 0 MUSCULOSKELETAL SYSTEM Pain-Extremities 4 3 NERVOUS SYSTEM Dizziness 19* 8 Libido Decreased 1 0 Paresthesia 3 1 Somnolence 5* 3 RESPIRATORY SYSTEM Dyspnea 3 2 Nasal Congestion 6* 3 Sinusitis 3 1 SPECIAL SENSES Blurred Vision 2* 0 UROGENITAL SYSTEM Erectile Dysfunction 1 1 † Includes weakness, tiredness, lassitude and fatigue. * Statistically significant at p=0.05 level. The following adverse reactions associated with the use of terazosin were identified in clinical studies (≥1%) or during post-approval use of terazosin. Because some of these reactions were reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure: Body as a Whole: edema, facial edema; Cardiovascular System: chest pain, arrhythmia, vasodilation; Digestive System: abdominal pain, constipation, diarrhea, dry mouth, dyspepsia, flatulence, vomiting; Metabolic/Nutritional Disorders: gout; Musculoskeletal System: arthralgia, arthritis, joint disorder, myalgia, neck pain, shoulder pain; Nervous System: anxiety, insomnia, nervousness, depression; Respiratory System: bronchitis, cold symptoms, epistaxis, increased cough, pharyngitis; Skin and Appendages: pruritus, rash, sweating; Special Senses: abnormal vision, conjunctivitis, tinnitus; Urogenital System: urinary frequency, urinary incontinence primarily reported in postmenopausal women; Adverse reactions were usually mild or moderate in intensity but sometimes were serious enough to interrupt treatment. The adverse reactions that were most bothersome, reported as reason for discontinuation therapy by at least 0.5% of the terazosin group and being reported more often than in the placebo group are shown in Table 4. Table 4. Discontinuations During Placebo-Controlled Studies of Terazosin in Patients with Hypertension Body System Terazosin (N=859) % Placebo (N=506) % BODY AS A WHOLE Asthenia 1.6% 0.0% Headache 1.3% 1.0% CARDIOVASCULAR SYSTEM Palpitations 1.4% 0.2% Postural Hypotension 0.5% 0.0% Syncope 0.5% 0.2% Tachycardia 0.6% 0.0% DIGESTIVE SYSTEM Nausea 0.8% 0.0% METABOLIC AND NUTRITIONAL DISORDERS Peripheral Edema 0.6% 0.0% NERVOUS SYSTEM Dizziness 3.1% 0.4% Paresthesia 0.8% 0.2% Somnolence 0.6% 0.2% RESPIRATORY SYSTEM Dyspnea 0.9% 0.6% Nasal Congestion 0.6% 0.0% SPECIAL SENSES Blurred Vision 0.6% 0.0% 6.2 Post-marketing Experience The following adverse reactions have been identified during postapproval use of terazosin. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Blood and Lymphatic System: thrombocytopenia Cardiovascular System: atrial fibrillation Skin and Appndages: allergic reactions, including anaphylaxis Urogenital System: priapism During cataract surgery, a variant of small pupil syndrome known as intraoperative floppy iris syndrome (IFIS) has been reported in association with alpha-1 antagonist therapy [see Warnings and Precautions (5.5)] .
adverse reactions table
<table cellspacing="0" cellpadding="0" border="0" width="642"><colgroup><col width="46.6493506493507%"/><col width="25.4337662337662%"/><col width="27.9168831168831%"/></colgroup><tbody><tr styleCode="Botrule"><td styleCode="Lrule Rrule" colspan="3" align="center" valign="middle"><content styleCode="bold">Table 1. Adverse Reactions Reported During Placebo-Controlled Studies of Terazosin in Patients with Benign</content><content styleCode="bold"> Prostatic Hyperplasia</content> </td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule" align="center" valign="middle"><content styleCode="bold">Body System</content> </td><td styleCode="Rrule" align="center" valign="middle"><content styleCode="bold">Terazosin</content> <content styleCode="bold">(N=636)</content> <content styleCode="bold">%</content> </td><td styleCode="Rrule" align="center" valign="middle"><content styleCode="bold">Placebo</content> <content styleCode="bold">(N=360)</content> <content styleCode="bold">%</content> </td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule" valign="middle"><content styleCode="bold">BODY AS A WHOLE</content> </td><td styleCode="Rrule" align="center" valign="middle"> </td><td styleCode="Rrule" align="center" valign="middle"> </td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule" valign="middle">†Asthenia </td><td styleCode="Rrule" align="center" valign="middle">7* </td><td styleCode="Rrule" align="center" valign="middle">3 </td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule" valign="middle">Flu Syndrome </td><td styleCode="Rrule" align="center" valign="middle">2 </td><td styleCode="Rrule" align="center" valign="middle">2 </td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule" valign="middle">Headache </td><td styleCode="Rrule" align="center" valign="middle">5 </td><td styleCode="Rrule" align="center" valign="middle">6 </td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule" valign="middle"><content styleCode="bold">CARDIOVASCULAR SYSTEM</content> </td><td styleCode="Rrule" align="center" valign="middle"> </td><td styleCode="Rrule" align="center" valign="middle"> </td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule" valign="middle">Hypotension </td><td styleCode="Rrule" align="center" valign="middle">1 </td><td styleCode="Rrule" align="center" valign="middle">1 </td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule" valign="middle">Palpitations </td><td styleCode="Rrule" align="center" valign="middle">1 </td><td styleCode="Rrule" align="center" valign="middle">1 </td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule" valign="middle">Postural Hypotension </td><td styleCode="Rrule" align="center" valign="middle">4* </td><td styleCode="Rrule" align="center" valign="middle">1 </td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule" valign="middle">Syncope </td><td styleCode="Rrule" align="center" valign="middle">1 </td><td styleCode="Rrule" align="center" valign="middle">0 </td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule" valign="middle"><content styleCode="bold">DIGESTIVE SYSTEM</content> </td><td styleCode="Rrule" align="center" valign="middle"> </td><td styleCode="Rrule" align="center" valign="middle"> </td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule" valign="middle">Nausea </td><td styleCode="Rrule" align="center" valign="middle">2 </td><td styleCode="Rrule" align="center" valign="middle">1 </td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule" colspan="3" valign="middle"><content styleCode="bold">METABOLIC AND NUTRITIONAL DISORDERS</content> </td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule" valign="middle">Peripheral Edema </td><td styleCode="Rrule" align="center" valign="middle">1 </td><td styleCode="Rrule" align="center" valign="middle">0 </td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule" valign="middle">Weight Gain </td><td styleCode="Rrule" align="center" valign="middle">1 </td><td styleCode="Rrule" align="center" valign="middle">0 </td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule" valign="middle"><content styleCode="bold">NERVOUS SYSTEM</content> </td><td styleCode="Rrule" align="center" valign="middle"> </td><td styleCode="Rrule" align="center" valign="middle"> </td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule" valign="middle">Dizziness </td><td styleCode="Rrule" align="center" valign="middle">9* </td><td styleCode="Rrule" align="center" valign="middle">4 </td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule" valign="middle">Somnolence </td><td styleCode="Rrule" align="center" valign="middle">4 </td><td styleCode="Rrule" align="center" valign="middle">2 </td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule" valign="middle">Vertigo </td><td styleCode="Rrule" align="center" valign="middle">1 </td><td styleCode="Rrule" align="center" valign="middle">0 </td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule" valign="middle"><content styleCode="bold">RESPIRATORY SYSTEM</content> </td><td styleCode="Rrule" align="center" valign="middle"> </td><td styleCode="Rrule" align="center" valign="middle"> </td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule" valign="middle">Dyspnea </td><td styleCode="Rrule" align="center" valign="middle">2 </td><td styleCode="Rrule" align="center" valign="middle">1 </td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule" valign="middle">Nasal Congestion/Rhinitis </td><td styleCode="Rrule" align="center" valign="middle">2* </td><td styleCode="Rrule" align="center" valign="middle">0 </td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule" valign="middle"><content styleCode="bold">UROGENITAL SYSTEM</content> </td><td styleCode="Rrule" align="center" valign="middle"> </td><td styleCode="Rrule" align="center" valign="middle"> </td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule" valign="middle">Erectile Dysfunction </td><td styleCode="Rrule" align="center" valign="middle">2* </td><td styleCode="Rrule" align="center" valign="middle">1 </td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule" valign="middle">Urinary Tract Infection </td><td styleCode="Rrule" align="center" valign="middle">1 </td><td styleCode="Rrule" align="center" valign="middle">4* </td></tr><tr><td styleCode="Lrule Rrule" colspan="3" valign="middle">† Includes weakness, tiredness, lassitude and fatigue. * p ≤ 0.05, comparison between groups. </td></tr></tbody></table>
adverse reactions table
<table cellspacing="0" cellpadding="0" border="0" width="628"><colgroup><col width="46.4289504404118%"/><col width="29.6084049665712%"/><col width="23.9626445930171%"/></colgroup><tbody><tr styleCode="Botrule"><td styleCode="Lrule Rrule" colspan="3" align="center" valign="middle"><content styleCode="bold">Table 2. Discontinuation Rates During Placebo-Controlled Studies of Terazosin in Patients with Benign Prostatic Hyperplasia</content> </td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule" align="center" valign="middle"><content styleCode="bold">Body System</content> </td><td styleCode="Rrule" align="center" valign="middle"><content styleCode="bold">Terazosin</content> <content styleCode="bold">(N=636)</content> <content styleCode="bold">%</content> </td><td styleCode="Rrule" align="center" valign="middle"><content styleCode="bold">Placebo</content> <content styleCode="bold">(N=360)</content> <content styleCode="bold">%</content> </td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule" valign="middle"><content styleCode="bold">BODY AS A WHOLE</content> </td><td styleCode="Rrule" align="center" valign="middle"> </td><td styleCode="Rrule" align="center" valign="middle"> </td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule" valign="middle">Fever </td><td styleCode="Rrule" align="center" valign="middle">0.5% </td><td styleCode="Rrule" align="center" valign="middle">0.0% </td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule" valign="middle">Headache </td><td styleCode="Rrule" align="center" valign="middle">1.1% </td><td styleCode="Rrule" align="center" valign="middle">0.8% </td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule" valign="middle"><content styleCode="bold">CARDIOVASCULAR SYSTEM</content> </td><td styleCode="Rrule" align="center" valign="middle"> </td><td styleCode="Rrule" align="center" valign="middle"> </td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule" valign="middle">Postural Hypotension </td><td styleCode="Rrule" align="center" valign="middle">0.5% </td><td styleCode="Rrule" align="center" valign="middle">0.0% </td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule" valign="middle">Syncope </td><td styleCode="Rrule" align="center" valign="middle">0.5% </td><td styleCode="Rrule" align="center" valign="middle">0.0% </td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule" valign="middle"><content styleCode="bold">DIGESTIVE SYSTEM</content> </td><td styleCode="Rrule" align="center" valign="middle"> </td><td styleCode="Rrule" align="center" valign="middle"> </td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule" valign="middle">Nausea </td><td styleCode="Rrule" align="center" valign="middle">0.5% </td><td styleCode="Rrule" align="center" valign="middle">0.3% </td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule" valign="middle"><content styleCode="bold">NERVOUS SYSTEM</content> </td><td styleCode="Rrule" align="center" valign="middle"> </td><td styleCode="Rrule" align="center" valign="middle"> </td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule" valign="middle">Dizziness </td><td styleCode="Rrule" align="center" valign="middle">2.0% </td><td styleCode="Rrule" align="center" valign="middle">1.1% </td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule" valign="middle">Vertigo </td><td styleCode="Rrule" align="center" valign="middle">0.5% </td><td styleCode="Rrule" align="center" valign="middle">0.0% </td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule" valign="middle"><content styleCode="bold">RESPIRATORY SYSTEM</content> </td><td styleCode="Rrule" align="center" valign="middle"> </td><td styleCode="Rrule" align="center" valign="middle"> </td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule" valign="middle">Dyspnea </td><td styleCode="Rrule" align="center" valign="middle">0.5% </td><td styleCode="Rrule" align="center" valign="middle">0.3% </td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule" valign="middle"><content styleCode="bold">SPECIAL SENSES</content> </td><td styleCode="Rrule" align="center" valign="middle"> </td><td styleCode="Rrule" align="center" valign="middle"> </td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule" valign="middle">Blurred Vision/Amblyopia </td><td styleCode="Rrule" align="center" valign="middle">0.6% </td><td styleCode="Rrule" align="center" valign="middle">0.0% </td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule" valign="middle"><content styleCode="bold">UROGENITAL SYSTEM</content> </td><td styleCode="Rrule" align="center" valign="middle"> </td><td styleCode="Rrule" align="center" valign="middle"> </td></tr><tr><td styleCode="Lrule Rrule" valign="middle">Urinary Tract Infection </td><td styleCode="Rrule" align="center" valign="middle">0.6% </td><td styleCode="Rrule" align="center" valign="middle">0.0% </td></tr></tbody></table>
adverse reactions table
<table cellspacing="0" cellpadding="0" border="0" width="628"><colgroup><col width="50.3553622573459%"/><col width="24.822318871327%"/><col width="24.822318871327%"/></colgroup><tbody><tr styleCode="Botrule"><td styleCode="Lrule Rrule" colspan="3" valign="top"><content styleCode="bold">Table 3. Adverse Reactions Reported During Placebo-Controlled Studies of Terazosin in Patients with Hypertension</content> </td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule" align="center" valign="middle"><content styleCode="bold">Body System</content> </td><td styleCode="Rrule" align="center" valign="top"><content styleCode="bold">Terazosin</content> <content styleCode="bold">(N=859)</content> <content styleCode="bold">%</content> </td><td styleCode="Rrule" align="center" valign="top"><content styleCode="bold">Placebo</content> <content styleCode="bold">(N=506)</content> <content styleCode="bold">%</content> </td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule" valign="top"><content styleCode="bold">BODY AS A WHOLE</content> </td><td styleCode="Rrule" valign="top"> </td><td styleCode="Rrule" valign="top"> </td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule" valign="top">†Asthenia </td><td styleCode="Rrule" align="center" valign="top">11* </td><td styleCode="Rrule" align="center" valign="top">4 </td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule" valign="top">Back Pain </td><td styleCode="Rrule" align="center" valign="top">2 </td><td styleCode="Rrule" align="center" valign="top">1 </td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule" valign="top"><content styleCode="bold">CARDIOVASCULAR SYSTEM</content> </td><td styleCode="Rrule" align="center" valign="top"> </td><td styleCode="Rrule" align="center" valign="top"> </td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule" valign="top">Palpitations </td><td styleCode="Rrule" align="center" valign="top">4* </td><td styleCode="Rrule" align="center" valign="top">1 </td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule" valign="top">Postural Hypotension </td><td styleCode="Rrule" align="center" valign="top">1 </td><td styleCode="Rrule" align="center" valign="top">0 </td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule" valign="top">Tachycardia </td><td styleCode="Rrule" align="center" valign="top">2 </td><td styleCode="Rrule" align="center" valign="top">1 </td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule" valign="top"><content styleCode="bold">DIGESTIVE SYSTEM</content> </td><td styleCode="Rrule" align="center" valign="top"> </td><td styleCode="Rrule" align="center" valign="top"> </td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule" valign="top">Nausea </td><td styleCode="Rrule" align="center" valign="top">4* </td><td styleCode="Rrule" align="center" valign="top">1 </td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule" colspan="3" valign="top"><content styleCode="bold">METABOLIC AND NUTRITIONAL DISORDERS</content> </td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule" valign="top">Peripheral Edema </td><td styleCode="Rrule" align="center" valign="top">6* </td><td styleCode="Rrule" align="center" valign="top">2 </td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule" valign="top">Weight Gain </td><td styleCode="Rrule" align="center" valign="top">1 </td><td styleCode="Rrule" align="center" valign="top">0 </td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule" colspan="3" valign="top"><content styleCode="bold">MUSCULOSKELETAL SYSTEM</content> </td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule" valign="top">Pain-Extremities </td><td styleCode="Rrule" align="center" valign="top">4 </td><td styleCode="Rrule" align="center" valign="top">3 </td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule" valign="top"><content styleCode="bold">NERVOUS SYSTEM</content> </td><td styleCode="Rrule" valign="top"> </td><td styleCode="Rrule" valign="top"> </td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule" valign="top">Dizziness </td><td styleCode="Rrule" align="center" valign="top">19* </td><td styleCode="Rrule" align="center" valign="top">8 </td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule" valign="top">Libido Decreased </td><td styleCode="Rrule" align="center" valign="top">1 </td><td styleCode="Rrule" align="center" valign="top">0 </td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule" valign="top">Paresthesia </td><td styleCode="Rrule" align="center" valign="top">3 </td><td styleCode="Rrule" align="center" valign="top">1 </td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule" valign="top">Somnolence </td><td styleCode="Rrule" align="center" valign="top">5* </td><td styleCode="Rrule" align="center" valign="top">3 </td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule" valign="top"><content styleCode="bold">RESPIRATORY SYSTEM</content> </td><td styleCode="Rrule" valign="top"> </td><td styleCode="Rrule" valign="top"> </td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule" valign="top">Dyspnea </td><td styleCode="Rrule" align="center" valign="top">3 </td><td styleCode="Rrule" align="center" valign="top">2 </td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule" valign="top">Nasal Congestion </td><td styleCode="Rrule" align="center" valign="top">6* </td><td styleCode="Rrule" align="center" valign="top">3 </td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule" valign="top">Sinusitis </td><td styleCode="Rrule" align="center" valign="top">3 </td><td styleCode="Rrule" align="center" valign="top">1 </td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule" valign="top"><content styleCode="bold">SPECIAL SENSES</content> </td><td styleCode="Rrule" valign="top"> </td><td styleCode="Rrule" valign="top"> </td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule" valign="top">Blurred Vision </td><td styleCode="Rrule" align="center" valign="top">2* </td><td styleCode="Rrule" align="center" valign="top">0 </td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule" valign="top"><content styleCode="bold">UROGENITAL SYSTEM</content> </td><td styleCode="Rrule" valign="top"> </td><td styleCode="Rrule" valign="top"> </td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule" valign="top">Erectile Dysfunction </td><td styleCode="Rrule" align="center" valign="top">1 </td><td styleCode="Rrule" align="center" valign="top">1 </td></tr><tr><td styleCode="Lrule Rrule" colspan="3" valign="top">† Includes weakness, tiredness, lassitude and fatigue. * Statistically significant at p=0.05 level. </td></tr></tbody></table>
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.